Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.02
$0.00
▼
$0.11
$16K-0.4430,352 shs3,004 shs
CDT Equity Inc. stock logo
CDT
CDT Equity
$0.47
-29.1%		$31.48
$0.41
▼
$28,125.00
$15K1.5979,042 shs825,323 shs
Shineco stock logo
SISI
Shineco
$0.11
$0.03
$0.00
▼
$6.79
$44K-1.761,989 shs2 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3116,363 shs4,295 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
+50.00%-40.00%+200.00%-99.30%-99.55%
CDT Equity Inc. stock logo
CDT
CDT Equity
-8.08%-28.08%-89.44%-99.25%-99.98%
Shineco stock logo
SISI
Shineco
0.00%0.00%+52,400.00%+4,900.00%-91.25%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%0.00%+300.00%-92.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.02
$0.00
▼
$0.11
$16K-0.4430,352 shs3,004 shs
CDT Equity Inc. stock logo
CDT
CDT Equity
$0.47
-29.1%		$31.48
$0.41
▼
$28,125.00
$15K1.5979,042 shs825,323 shs
Shineco stock logo
SISI
Shineco
$0.11
$0.03
$0.00
▼
$6.79
$44K-1.761,989 shs2 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3116,363 shs4,295 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
+50.00%-40.00%+200.00%-99.30%-99.55%
CDT Equity Inc. stock logo
CDT
CDT Equity
-8.08%-28.08%-89.44%-99.25%-99.98%
Shineco stock logo
SISI
Shineco
0.00%0.00%+52,400.00%+4,900.00%-91.25%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%0.00%+300.00%-92.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
CDT Equity Inc. stock logo
CDT
CDT Equity
1.00
SellN/AN/A
Shineco stock logo
SISI
Shineco
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SYRS, SISI, CDT, and BPTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
CDT Equity Inc. stock logo
CDT
CDT Equity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
CDT Equity Inc. stock logo
CDT
CDT Equity
N/AN/AN/AN/AN/AN/A
Shineco stock logo
SISI
Shineco
$9.60M0.00N/AN/A$4,679.15 per share0.00
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.03N/AN/A$0.79 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
CDT Equity Inc. stock logo
CDT
CDT Equity
-$39.22M-$83,857.75N/AN/AN/AN/A-72.25%-55.44%N/A
Shineco stock logo
SISI
Shineco
-$22.45M-$204.00N/AN/AN/A-380.55%-79.89%-33.01%N/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%10/29/2026 (Estimated)

Latest SYRS, SISI, CDT, and BPTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A-$217.75N/A-$8.71N/AN/A
7/15/2026Q1 2026
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A-$1,390.00N/A-$55.60N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
CDT Equity Inc. stock logo
CDT
CDT Equity
N/AN/AN/AN/AN/A
Shineco stock logo
SISI
Shineco
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A
0.13
0.13
Shineco stock logo
SISI
Shineco
N/A
0.72
0.71
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
CDT Equity Inc. stock logo
CDT
CDT Equity
3.29%
Shineco stock logo
SISI
Shineco
4.08%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
CDT Equity Inc. stock logo
CDT
CDT Equity
7.34%
Shineco stock logo
SISI
Shineco
0.02%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
CDT Equity Inc. stock logo
CDT
CDT Equity
431,00029,000Not Optionable
Shineco stock logo
SISI
Shineco
119415,000415,000Not Optionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionNo Data

Recent News About These Companies

Syros approves wind-down: what it means for Syros Pharmaceuticals stock
October 6, 2026  |  ad-hoc-news.deA
Syros Pharmaceuticals stock trades at USD 0.0004 after delisting
October 4, 2026  |  ad-hoc-news.deA
SYRS stock reflects a 2025 Nasdaq delisting and wind down
September 30, 2026  |  ad-hoc-news.deA
Syros Pharmaceuticals stock holds steady as market data reset
September 23, 2026  |  ad-hoc-news.deA
Syros Announces Pricing of $75.6 Million Public Offering of Common Stock
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20210119006194/en/Syros-Announces-Pricing-of-%2475.6-Million-Public-Offering-of-Common-Stock
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals
April 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/rege-nephro-buys-tamibarotene-related-assets-from-syros-pharmaceuticals/ar-AA1CX7u7
Syros Pharmaceuticals trading resumes
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-trading-resumes-1034427505
Syros Pharmaceuticals Plans to Wind Down Operations
March 1, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/syros-pharmaceuticals-plans-to-wind-down-operations-948b139e
Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-voluntarily-delists-from-nasdaq-deregisters-common-stock-1034427422
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
February 28, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250228459350/en/syros-announces-voluntary-delisting-from-nasdaq-and-sec-deregistration/
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline
January 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/syros-pharmaceuticals-stock-hits-52-week-low-at-0-18-amid-steep-decline/ar-AA1y4cfB
Syros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?
January 18, 2025  |  bovnews.comB
What’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?
January 16, 2025  |  bovnews.comB
SYRS’s Latest Surge: What’s Behind the Spike?
January 6, 2025  |  bovnews.comB
The SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines Again
January 2, 2025  |  bovnews.comB
Analysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?
December 31, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It Appears
December 27, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes Revealed
December 26, 2024  |  bovnews.comB
What’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?
December 14, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock Settles at $0.24: What’s Contributing to This Price Point?
December 7, 2024  |  bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.0003 0.00 (0.00%)
As of 10/12/2026 09:30 AM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

CDT Equity stock logo

CDT Equity NASDAQ:CDT

$0.47 -0.19 (-29.09%)
As of 03:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Shineco stock logo

Shineco NASDAQ:SISI

$0.10 0.00 (0.00%)
As of 10/12/2026

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0004 0.00 (0.00%)
As of 11:50 AM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas